Against this backdrop, mwb research is hosting an online roundtable with Thomas Fischler (Head of Treasury & Investor Relations) on April 14, 2026, at 2:00 p.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-04-14-14-00/DRW3-GR.

Against this backdrop, mwb research is hosting an online roundtable with Sven Köpsel (Vice President of Investor Relations & Communications) on April 14, 2026, at 1:30 p.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-04-14-13-30/SMHN-GR.

Against this backdrop, mwb research is hosting an online roundtable with Johannes Braun (Senior Manager, Investor Relations) on April 14, 2026, at 12:00 p.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-04-14-12-00/TKMS-GR.

Against this backdrop, mwb research is hosting an online roundtable with Sophia Kursawe (Senior Manager, Investor Relations) on April 14, 2026, at 11:30 a.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-04-14-11-30/KBX-GR.

Against this backdrop, mwb research is hosting an online roundtable with Maximilian König & Christian Weiß (Senior Managers, Investor Relations) on April 14, 2026, at 11:00 a.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-04-14-11-00/R3NK-GR.

Against this backdrop, mwb research is hosting an online roundtable with Robert von Wülfing (CEO) on April 14, 2026, at 10:30 a.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-04-14-10-30/AAD-GR.

Against this backdrop, mwb research is hosting an online roundtable with Andreas Theisen (Head of IR & Sustainability) on April 14, 2026, at 10:00 a.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-04-14-10-00/JEN-GR.

Redcare Pharmacy (RDC) reported a solid start to 2026, with Q1 group revenue up 18% yoy to EUR 848m, ahead of its FY26 guidance of 13-15% growth. Non-Rx grew 10% to EUR 533m, in line with the guided 8-10% range, while Rx increased 35% to EUR 315m, driven by strong momentum in Germany. German non-Rx growth improved compared to Q4 following a period of lower marketing spend. The company confirmed its FY26 outlook. Overall, the business is tracking as expected within the reset framework. We confirm our BUY rating and EUR 95.00 price target, with further detail on profitability expected in May. The full update can be downloaded under https://research-hub.de/companies/redcare-pharmacy-nv

We downgrade LANXESS to HOLD from BUY ahead of Q1, as we expect the company to remain firmly in the trough, with no near-term improvement in volumes or utilization amid weak end-markets, persistent pricing pressure and structurally high European energy costs. Recent price increases appear largely defensive, reflecting cost pass-through rather than pricing power. At the same time, the Middle East energy shock adds further pressure to an already fragile backdrop, reinforcing Europe’s cost disadvantage and delaying the recovery timeline toward the end of H2 2026. With the shares now trading around our fair value of EUR 17.00, we see limited near-term upside, as further re-rating would require greater visibility on volumes and earnings inflection. The full update can be downloaded under https://research-hub.de/companies/lanxess-ag

Company Name: EPH Group AG ISIN: AT0000A34DM3   Reason for the research: Update Recommendation: BUY Target price: EUR 102 Target price on sight of: 12 months Last rating change: Analyst: Philipp Sennewald EPH secures another premium alpine resort project Last week, EPH announced the signing of an agreement to acquire a high-quali [ … ]